No Data
Wuhan Hiteck Biological Pharma (300683.SZ): plans to reduce the subscribed capital contribution amount of the Fund.
On March 18, Gelonghui reported that Wuhan Hiteck Biological Pharma (300683.SZ) announced that based on adjustments to the Global Strategy, it was agreed among all partners to change the subscribed capital contribution of the Q ingning Fund from RMB 240 million to RMB 120 million. The company's subscribed capital contribution decreased from RMB 10 million to RMB 5 million, reducing the subscribed capital contribution by RMB 5 million. This reduction in the subscribed capital contribution of the Q ingning Fund will not affect the normal operation of the fund, is beneficial for the company to integrate internal resources, improve the efficiency of MMF utilization, meet operational needs, and align with the strategic development requirements of the company.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Wuhan Hiteck Biological Pharma (300683.SZ) announced a预亏,预计 annual net loss of 57 million yuan - 78 million yuan.
Wuhan Hiteck Biological Pharma (300683.SZ) disclosed its performance forecast for 2024, and the company expects the net profit attributable to the Shareholders of the listed company...
Haite Biotech: 2024 performance forecast
Wuhan Hiteck Biological Pharma (300683.SZ): The company has changed its pharmaceutical production license, and the production scope now includes suppositories.
On December 27, GELONGHUI reported that Wuhan Hiteck Biological Pharma (300683.SZ) stated on an investor interaction platform that the company recently obtained a new "Pharmaceutical Production License" issued by the Hubei Provincial Drug Administration, approving the application for the change of the "Pharmaceutical Production License." The new license adds suppository preparations to the range of production, with other content unchanged. Due to the need for the transfer of the suppository preparation approval number, this "Pharmaceutical Production License" adds the production range for Suppository Preparation B. The above changes will not have a significant impact on the company's performance. Investors are urged to invest rationally and pay attention to investment risks.